Celltech Codeprex Approved For 12-Hour Cough Suppression
This article was originally published in The Pink Sheet Daily
Celltech expects the codeine-based antitussive to hit retail pharmacy shelves by the fourth quarter. The extended-release formulation eliminates the need for middle of the night dosing, the company says.
You may also be interested in...
The licensing agreement gives Celltech a means through which to commercialize the TNF inhibitor should the companies' proposed $2.7 bil. merger agreement fall through. UCB/Celltech will be fifth largest biotech company worldwide.
Senior VP-Global Clinical & Pharmaceutical Development Elliott Sigal is acting president of Bristol-Myers Squibb’s research institute following the death of James Palmer.
The four-pronged plan will address “bio-burden,” manufacturing techniques, quality systems and execution, CEO Pien says. Chiron has met twice with U.K. authorities and hopes to realize similar progress with FDA soon.